

Index

- 3-D processing techniques 36, 65–66
- 5 fluorouracil (5FU)-based chemoradiation 168–169
- acinar cell carcinoma (ACC) 20–21, 175
- adenosquamous carcinomas 13
- anaplastic carcinoma 13–14, 175
- angiomyolipoma 183
- atypical mass, biopsies of 156
- autoimmune pancreatitis (AIP) 68, 184–185
- biologic agents for advanced pancreatic cancer 170–171
- carcinoembryonic antigen (CEA), elevated level in mucinous cysts 141–142
- carcinoid tumors 109–110
- CEMRA (contrast enhanced magnetic resonance angiography) 53–54
- chemoradiotherapy and chemotherapy 167–170
- chronic pancreatitis 2, 38–39, 184
- clinical presentation 29, 58
 - autoimmune pancreatitis 184–185
 - head of pancreas cancer 154–155
 - hyperfunctioning NENs 105–110
 - non-hyperfunctioning NENs 110
 - pancreatic cystic neoplasms 83
- colloid carcinoma 11–13, 19
- computed tomography (CT) 60
 - CT-guided FNA 135–136
 - interpretation
 - detection 66–68
 - staging 68–74
 - patient preparation 63
 - procedure when no mass seen 156
 - staging
 - technique 60–63
 - testing typical masses 155–156
 - see also* multi-detector CT (MDCT) techniques
- contrast agents
 - intravenous (IV) 31–32
 - gadolinium-based 77, 92
 - injection rate 32, 63
 - mangafodipir trisodium 75
 - orally administered 30, 47, 63, 74
- contrast-enhanced magnetic resonance angiography (CEMRA) 53–54
- contrast-enhanced MR sequences 49–50
- corticotropinoma 109
- cystic lesions, EUS evaluation of 138–142
- cystic pancreatic neoplasms 83–84
 - cystic pancreatic endocrine neoplasms (PENs) 96–98
- intraductal papillary mucinous neoplasms (IPMNs) 90–94
 - management of 99
- MDCT imaging 40
- miscellaneous and rare lesions 98–99
- mucinous cystic neoplasms (MCNs) 86–90
- serous cystic neoplasms (SCNs) 85
- solid pseudopapillary epithelial neoplasm (SPEN) 94–96
- cytogenetics of pancreatic cancer 1, 5
 - differences from IPMN 4
 - implications for diagnosis/management 6
- diagnosis of pancreatic cancer
 - biopsies resulting from CT findings 155–156
 - cystic pancreatic lesions 99
 - cytogenetics 6
 - fine needle aspiration (FNA) 133–136
 - goals of preoperative imaging 59
 - role of endoscopic ultrasound (EUS) 131–133
 - see also* imaging evaluation of PC
- diffusion weighted imaging (DWI) 54
- ductal adenocarcinoma *see* pancreatic cancer (PC)
- ectopic hormones, tumors producing 109–110
- endocrine tumors 23–24, 96–98
 - see also* neuroendocrine neoplasms (NEN)
- endoscopic retrograde cholangiopancreatography (ERCP) 156

194 Index

- endoscopic ultrasound (EUS) 78–79, 84, 130–131
 - in diagnosis of atypical mass 156
 - diagnosis of pancreatic adenocarcinoma 131–133
 - evaluation of cystic lesions 138–142
 - in the evaluation of PEN 142–144
 - staging of pancreatic adenocarcinoma 136–137
 - with fine needle aspiration (EUS-FNA) 133–136
- epidemiology of pancreatic cancer 1–2
- erlotinib treatment 171
- familial PC syndrome 6
- fine needle aspiration (FNA), EUS 133–136
- focal fatty replacement, mimicking a tumor 188–189
- focal pancreatitis 68
 - EUS-FNA for evaluation of 135
 - groove pancreatitis 185–186
- gastrinomas 107, 113–115, 122
- Gastrointestinal Tumor Study Group (GITSG) 168–169
- gemcitabine treatment
 - locally advanced cancer 167–169
 - metastatic cancer 170–171
- genetics 1
 - cytogenetics of PC 5
 - implications for diagnosis and management 6
 - mucinous cystic neoplasms (MCNs) 4–5
 - syndromes with predisposition to PC 5–6
- giant cell carcinomas 13–14, 177
- glucagonoma 107, 115–116
- GRFoma 109
- groove pancreatitis 185–186
- H-NENs *see* hyperfunctioning NENs
- hereditary PC syndromes 5–6
- hybrid PET-CT scanners 79–80
- hyperfunctioning NENs (H-NENs)
 - radiographic imaging features and results 110–118
 - tumors producing ectopic hormones 109–110
 - tumors producing islet- and gut-related hormones 105–108
- imaging evaluation of PC 58–59
 - computed tomography (CT) 60–63
 - contrast dose, injection rate and scan timing 63–65
 - detection of pancreatic ductal cancer 59
 - goals of preoperative imaging 59
 - magnetic resonance imaging (MRI) 74–78
 - patient preparation 63, 74
 - positron emission tomography (PET) 79–80
 - post processing 65–66
 - CT interpretation
 - detection 66–68
 - staging 68–74
 - staging 78
 - see also* endoscopic ultrasound; multi-detector CT (MDCT) techniques
 - injection rate, contrast agent 32, 63
 - insulinomas 105–107, 110–113
 - detection using EUS 143
 - intraductal papillary mucinous neoplasms (IPMNs) 1, 2–4, 17–19
 - association with colloid carcinoma 11–13, 19
 - imaging of 90–94
 - intrapaneatic accessory spleen 187–188
 - invasive carcinoma, MCN 20
 - IPMNs *see* intraductal papillary mucinous neoplasms (IPMNs)
 - islet- and gut-related hormones, tumors producing 105–108
 - KRAS oncogene, mutation of 4, 6
 - leiomyosarcoma 180
 - lipoma 182
 - liver metastases 116, 122
 - locally advanced pancreatic cancer, treatment of 166–170
 - lymphangioma 180
 - lymphoepithelial cyst (LEC) 98–99, 180–182
 - lymphoma 177–178
 - macroscopic precursors of PC
 - intraductal papillary mucinous neoplasms (IPMNs) 2–4
 - mucinous cystic neoplasms (MCNs) 4–5
 - magnetic resonance cholangiopancreatography (MRCP) 50–53
 - magnetic resonance spectroscopy (MRS) 54–55
 - mangafodipir trisodium 75
 - mass-forming chronic pancreatitis 184
 - MCNs *see* mucinous cystic neoplasms (MCNs)
 - MDCT *see* multi-detector CT (MDCT) techniques
 - medullary carcinoma 14–16
 - mesenchymal tumors 182–183
 - lipoma 182
 - lymphangioma 180
 - lymphoepithelial cyst 180–182
 - sarcoma 180
 - true cysts 183
 - metastatic pancreatic cancer 178–180
 - H-HEN, liver metastases 122
 - treatment of 170–171
 - VIPomas, liver metastases 116
 - microscopic precursors of PC 2
 - mimics of pancreatic cancer 175
 - autoimmune pancreatitis 68, 184–185
 - focal fatty replacement 188–189
 - focal pancreatitis 68
 - mortality rates following surgery 58, 150, 158
 - MRI techniques 46, 74–75
 - advantages over CT 75
 - comparison to CT technology 74, 77–78
 - contrast-enhanced MR sequences 49–50
 - detection of pancreatic adenocarcinomas 77
 - MRCP (Magnetic Resonance Cholangiopancreatography) 50–53
 - non-contrast MR sequences 47–49
 - normal pancreas 76–77

- patient preparation 47, 74
 - staging 78
 - supplementary and emerging techniques 53–55
 - mucinous adenocarcinomas 163
 - mucinous cystic neoplasms (MCNs) 1
 - histologic features 19–20
 - imaging evaluation 86–90
 - invasive carcinoma 20
 - precursor of pancreatic cancer 4–5
 - mucinous non-cystic carcinoma 11–13
 - multi-detector CT (MDCT) techniques 28
 - accuracy of 39–40
 - acquisition parameters 29
 - additional techniques 36–39
 - clinical indications 29
 - IV contrast and dose 31–32
 - for NENs 119–120
 - oral contrast 30
 - and other forms of pancreatic neoplasms 40
 - pancreatic protocol components 28–29
 - phasing and timing of scans 32
 - dual phase acquisition 33
 - matching to cardiac output 65
 - single phase acquisition 33
 - protocol example 64
 - radiation dose 29–30
 - reconstruction parameters 33–34
 - see also* computed tomography (CT)
- neoadjuvant chemotherapy 167–168
- neuroendocrine neoplasms (NENs) 104, 123
- H-NENs
 - clinical features of 105–110
 - radiographic imaging features and results 110–118
 - MDCT imaging 40
 - N-NENs
 - clinical features of 110
 - radiographic imaging features and results 118–119
 - role of imaging 119–122
 - treatment 122–123
 - see also* pancreatic endocrine neoplasms (PENs)
- non-contrast MR sequences 47–49
- non-neoplastic conditions
- autoimmune pancreatitis 68, 184–185
 - chronic pancreatitis 184
 - focal fatty replacement 188–189
 - groove pancreatitis 185–186
 - intrapaneatic accessory spleen 187–188
- non-hyperfunctioning NENs (N-NENs)
- clinical features of 110
 - radiographic imaging features and results 118–119
- non-syndromic tumors *see* non-hyperfunctioning NENs
- oncogenes 4, 5, 6
- osteoclast-like giant cell 14, 177
- pancreatectomy
- distal (body or tail) 159–161
 - total 152–154
- pancreatic cancer (PC) 1
- cytogenetics of 5
 - diagnosis of 131–133
 - epidemiology 1–2
 - hereditary syndromes 5–6
 - macroscopic precursors
 - IPMNs 2–4
 - MCNs 4–5
 - microscopic precursors 2
 - pathology of 10–16
 - see also* rare pancreatic neoplasms
- pancreatic ductal adenocarcinoma *see* pancreatic cancer (PC)
- pancreatic endocrine neoplasms (PENs) 23–24
- cystic PEN 96–98
 - EUS in evaluation of 142–144
 - see also* neuroendocrine neoplasms (NENs)
- pancreatic intraepithelial neoplasias (PanINs) 2, 16–17
- pancreatic neuroendocrine neoplasms *see* neuroendocrine neoplasms (NENs)
- pancreatoduodenectomy 150–152
- PanINs *see* pancreatic intraepithelial neoplasias
- parathyrinoma 109
- pathology of pancreatic neoplasms 10
- acinar cell carcinoma (ACC) 20–21
 - ductal adenocarcinoma 10–16
 - intraductal papillary mucinous neoplasm (IPMN) 17–19
 - mucinous cystic neoplasms (MCNs) 19–20
 - pancreatic endocrine neoplasm (PEN) 23–24
 - precursors to PC, PanIN 16–17
 - serous cystic neoplasms 24–25
 - solid pseudopapillary tumor (SPT) 21–22
- patient preparation for CT and MRI 47, 63, 74
- PC *see* pancreatic cancer
- PENs *see* pancreatic endocrine neoplasms
- positron emission tomography (PET) 79–80
- preventive measures 171
- pseudocysts 98, 138
- radiation doses, methods of minimizing 29–30
- radical antegrade modular pancreato-splenectomy (RAMPS) 159–160
- rare pancreatic neoplasms 175–177
- lymphoma 177–178
 - mesenchymal tumors 180–183
 - metastasis 178–180
 - solid pseudopapillary tumor (SPT) 21–22, 177
- renal cell carcinoma, pancreatic metastases from 178–180
- resection of pancreatic adenocarcinoma
- accuracy in predicting using CT signs 73
 - body and tail, rationale for 159–161
 - determination of resectability 156–158
 - head of pancreas, rationale for 150–152
 - predictors of non-resectability 73
- sarcoma 180
- scan timing 32–33, 50, 63–65
- schwannoma of the pancreas 182

196 Index

- SCNs *see* serous cystic neoplasms
- screening 171
- segmental pancreatic duct dilation 38–39
- selective arterial stimulation 110, 113, 121, 123, 143
- serous cystadenomas 139–140
- serous cystic neoplasms (SCNs) 24–25, 85
- signet ring cell carcinoma 13
- small cell carcinoma 177
- smoking, risk factor for PC 2
- solid pseudopapillary epithelial neoplasm (SPEN) 21–22, 94–96, 177
- solid pseudopapillary tumor (SPT) 21–22, 94–96, 177
- somatostatin receptor scintigraphy (SRS) 112, 113–115, 116, 120–121, 143
- somatostatinomas 108, 117
- SPEN *see* solid pseudopapillary epithelial neoplasm
- SPT *see* solid pseudopapillary tumor (SPT)
- staging laparoscopy 157–158, 162
- staging of pancreatic adenocarcinoma 68–74
 - distant staging 78
 - local staging 78
 - role of EUS 136–137
 - see also* surgical staging
- steady-state free precession (SSFP) imaging 54
- surgical staging 150
 - body and tail of pancreas
 - diagnosis and staging 160–162
 - rationale for resection 159–161
 - results of resection 162–163
 - head of pancreas
 - diagnosis
 - clinical presentation 154–155
 - using imaging techniques 155–156
 - rationale for surgical resection 150–152
 - results of resection 158
 - surgical staging of tumor of 156–158
- survival rates 1
 - acinar cell carcinoma 21
 - colloid carcinoma 13
 - glucagonoma 107
 - locally advanced cancer 166, 168–170
 - main pancreatic duct (MPD) IPMN following surgery 93
 - metastatic cancer 122, 170–171
 - mucinous cystic neoplasms (MCNs) 20, 90
 - non-hyperfunctioning NENs 110
 - pancreatic body and tail resection 162–163
 - pancreatic head resection 158
 - PEN following surgery 98
 - somatostatinomas 108
 - SPEN following surgery 96
 - symptoms 2–4, 29, 83
 - management of 171
 - syndromic tumors *see* hyperfunctioning NENs
 - teratoma of the pancreas 182–183
 - timing of scans 32–33, 50, 63–65
 - total pancreatectomy 152–154
 - transabdominal ultrasound 84, 112, 113
 - treatment 166
 - cystic pancreatic neoplasms 99
 - implications of cytogenetics 6
 - locally advanced pancreatic adenocarcinoma 166–170
 - metastatic pancreatic adenocarcinoma 170–171
 - neuroendocrine neoplasms (NENs) 122–123
 - symptomatic management 171
 - true cysts 183
 - tumor suppressor genes 5
 - undifferentiated (anaplastic or sarcomatoid) carcinoma 13–14
 - undifferentiated carcinoma with osteoclast-like giant cells 14
 - vascular invasion 36–38
 - criteria predicting extent of 69–73
 - EUS criteria for 136
 - VIPomas 107–108, 116
 - von Hippel–Lindau disease 27, 96, 183
 - Whipple procedure 150–152
 - Zollinger–Ellison syndrome 107, 108, 109, 113